

Supplemental Table S2. Allele Frequencies of HLA-B in Patients with ICI-T1DM

Allele	ICI-T1DM (n=14)			ICI-controls (n=26)			Controls (n=587,057) ^a	ICI-T1DM vs. ICI-controls	ICI-controls vs. controls
	Number	F, %	P value ^b	Number	F, %	P value ^b			
B*07:02	0	0.0	NS	2	7.7	NS	5.46	NS	NS
B*13:01	0	0.0	NS	0	0.0	NS	1.18	NS	NS
B*15:01	2	14.3	NS	3	11.5	NS	7.93	NS	NS
B*15:11	0	0.0	NS	2	7.7	NS	0.94	NS	NS
B*15:18	0	0.0	NS	0	0.0	NS	1.57	NS	NS
B*35:01	1	7.1	NS	3	11.5	NS	8.39	NS	NS
B*39:01	0	0.0	NS	0	0.0	NS	3.39	NS	NS
B*40:01	1	7.1	NS	2	7.7	NS	5.56	NS	NS
B*40:02	1	7.1	NS	2	7.7	NS	7.81	NS	NS
B*40:06	1	7.1	NS	2	7.7	NS	4.79	NS	NS
B*44:03	2	14.3	NS	2	7.7	NS	6.66	NS	NS
B*46:01	1	7.1	NS	3	11.5	NS	4.51	NS	NS
B*48:01	0	0.0	NS	0	0.0	NS	2.89	NS	NS
B*51:01	0	0.0	NS	0	0.0	NS	8.74	NS	NS
B*52:01	1	7.1	NS	3	11.5	NS	11.01	NS	NS
B*54:01	3	21.4	NS	2	7.7	NS	7.58	NS	NS
B*55:02	0	0.0	NS	0	0.0	NS	2.48	NS	NS
B*59:01	1	7.1	NS	0	0.0	NS	2.02	NS	NS
B*67:01	0	0.0	NS	0	0.0	NS	1.13	NS	NS
Others	0	0.0	NS	0	0.0	NS	5.96	NS	NS
Total	14	100.0		26	100.0		100.00		

Alleles with frequencies more than 1.0% in controls were included to the analysis (19 alleles).

HLA-B, human leukocyte antigen B; ICI-T1DM, immune-checkpoint inhibitor-induced type 1 diabetes mellitus; F, frequency of the allele; NS, not significant.

^aControl subjects: Japanese Society for Histocompatibility and Immunogenetics (<http://jshi.umin.ac.jp/standarization/file/JSHI-hyokialle-2021list.pdf>) (JSHI2021) [16]; ^bThe association of haplotype frequencies with each disease was analyzed using Fisher's exact test with 2×2 contingency tables.